moxifloxacin has been researched along with Dyspnea in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Chen, Y; Fang, Q; Hu, S; Jiang, J; Liang, T; Lu, S; Sheng, J; Wei, N; Wu, L; Zheng, S; Zhou, J | 1 |
| Fukao, A; Horikawa, S; Ikeue, T; Noguchi, S; Ohi, I; Sugita, T; Tanaka, E; Terashita, S; Yoshida, H | 1 |
| Diethelm, M; Schuster, S | 1 |
| Dannecker, G; Hess, S; Hospach, T; Magdorf, K; Nossal, R; Uhlemann, F | 1 |
| Arvis, P; Choudhri, SH; Haverstock, D; Kruesmann, F; Miravitlles, M; Perroncel, R | 1 |
1 review(s) available for moxifloxacin and Dyspnea
| Article | Year |
|---|---|
Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bronchitis, Chronic; Color; Disease Progression; Dyspnea; Female; Fluoroquinolones; Gentian Violet; Humans; Male; Moxifloxacin; Multicenter Studies as Topic; Phenazines; Pneumonia, Bacterial; Quinolines; Randomized Controlled Trials as Topic; Sex Factors; Sputum | 2012 |
4 other study(ies) available for moxifloxacin and Dyspnea
| Article | Year |
|---|---|
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.
Topics: Antibodies, Viral; Antipsychotic Agents; Antiviral Agents; Betacoronavirus; Bipolar Disorder; Brain; Chest Pain; China; Clinical Laboratory Techniques; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Testing; Darunavir; Dyspnea; Fever; Glucocorticoids; Humans; Indoles; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Olanzapine; Pandemics; Pharyngitis; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 | 2020 |
Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement.
Topics: Clarithromycin; Cough; Dyspnea; Exudates and Transudates; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections; Pleurisy; Tomography, X-Ray Computed | 2017 |
[Achilles heel of COPD].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspnea; Fluoroquinolones; Humans; Male; Mobility Limitation; Moxifloxacin; Ofloxacin; Prednisone; Pulmonary Disease, Chronic Obstructive; Quinolines; Respiratory Insufficiency; Rupture, Spontaneous; Ultrasonography | 2013 |
Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.
Topics: Acquired Hyperostosis Syndrome; Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Dyspnea; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Immunosuppressive Agents; Moxifloxacin; Quinolines; Severity of Illness Index; Shock, Septic; Treatment Outcome; Tuberculosis, Miliary; Tumor Necrosis Factor-alpha | 2011 |